Will Pizii | Authors

Articles

FDA Approves New Tablet Form for Acalabrutinib

August 05, 2022

Acalabrutinib’s new tablet formulation has been granted FDA approval for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and relapsed or refractory mantle cell lymphoma.